Sagent Pharmaceuticals introduces pamidronate disodium injection in single-dose vials

[News]

Sagent Pharmaceuticals, Inc., a privately held specialty pharmaceutical company, today announced that it has launched pamidronate disodium injection in single-dose vials containing 30 mg per 10 mL and 90 mg per 10 mL. Pamidronate disodium injection, the generic alternative of Novartis Pharmaceutical Company's Aredia®, is a bone resorption inhibitor. The 2008 U.S. market for pamidronate disodium approximated $17 million, according to IMS data.

More... (http://www.news-medical.net/news/20100120/Sagent-Pharmaceuticals-introduces-pamidronate-disodium-injection-in-single-dose-vials.aspx)